Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11


Potency of HIV-2-specific antibodies increase in direct association with loss of memory B cells.

Rocha C, Duarte J, Borrego P, Calado R, Marcelino JM, Tendeiro R, Valadas E, Sousa AE, Taveira N.

AIDS. 2017 Nov 13;31(17):2431-2433. doi: 10.1097/QAD.0000000000001661.


miRNA profiling of human naive CD4 T cells links miR-34c-5p to cell activation and HIV replication.

Amaral AJ, Andrade J, Foxall RB, Matoso P, Matos AM, Soares RS, Rocha C, Ramos CG, Tendeiro R, Serra-Caetano A, Guerra-Assunção JA, Santa-Marta M, Gonçalves J, Gama-Carvalho M, Sousa AE.

EMBO J. 2017 Feb 1;36(3):346-360. doi: 10.15252/embj.201694335. Epub 2016 Dec 19.


Development of synthetic light-chain antibodies as novel and potent HIV fusion inhibitors.

Cunha-Santos C, Figueira TN, Borrego P, Oliveira SS, Rocha C, Couto A, Cantante C, Santos-Costa Q, Azevedo-Pereira JM, Fontes CM, Taveira N, Aires-Da-Silva F, Castanho MA, Veiga AS, Goncalves J.

AIDS. 2016 Jul 17;30(11):1691-701. doi: 10.1097/QAD.0000000000001108.


Evolution of the human immunodeficiency virus type 2 envelope in the first years of infection is associated with the dynamics of the neutralizing antibody response.

Rocha C, Calado R, Borrego P, Marcelino JM, Bártolo I, Rosado L, Cavaco-Silva P, Gomes P, Família C, Quintas A, Skar H, Leitner T, Barroso H, Taveira N.

Retrovirology. 2013 Oct 24;10:110. doi: 10.1186/1742-4690-10-110.


Baseline susceptibility of primary HIV-2 to entry inhibitors.

Borrego P, Calado R, Marcelino JM, Bártolo I, Rocha C, Cavaco-Silva P, Doroana M, Antunes F, Maltez F, Caixas U, Barroso H, Taveira N.

Antivir Ther. 2012;17(3):565-70. doi: 10.3851/IMP1996. Epub 2012 Jan 25.


Genetic diversity and drug resistance profiles in HIV type 1- and HIV type 2-infected patients from Cape Verde Islands.

Oliveira V, Bártolo I, Borrego P, Rocha C, Valadas E, Barreto J, Almeida E, Antunes F, Taveira N.

AIDS Res Hum Retroviruses. 2012 May;28(5):510-22. doi: 10.1089/AID.2011.0174. Epub 2011 Sep 19.


Potent and broadly reactive HIV-2 neutralizing antibodies elicited by a vaccinia virus vector prime-C2V3C3 polypeptide boost immunization strategy.

Marcelino JM, Borrego P, Rocha C, Barroso H, Quintas A, Novo C, Taveira N.

J Virol. 2010 Dec;84(23):12429-36. doi: 10.1128/JVI.01102-10. Epub 2010 Sep 15.


HIV-1 genetic diversity and transmitted drug resistance in health care settings in Maputo, Mozambique.

Bártolo I, Casanovas J, Bastos R, Rocha C, Abecasis AB, Folgosa E, Mondlane J, Manuel R, Taveira N.

J Acquir Immune Defic Syndr. 2009 Jul 1;51(3):323-31.


Antiretroviral drug resistance surveillance among treatment-naive human immunodeficiency virus type 1-infected individuals in Angola: evidence for low level of transmitted drug resistance.

Bártolo I, Rocha C, Bartolomeu J, Gama A, Fonseca M, Mendes A, Cristina F, Thamm S, Epalanga M, Silva PC, Taveira N.

Antimicrob Agents Chemother. 2009 Jul;53(7):3156-8. doi: 10.1128/AAC.00110-09. Epub 2009 May 11.


The role of the humoral immune response in the molecular evolution of the envelope C2, V3 and C3 regions in chronically HIV-2 infected patients.

Borrego P, Marcelino JM, Rocha C, Doroana M, Antunes F, Maltez F, Gomes P, Novo C, Barroso H, Taveira N.

Retrovirology. 2008 Sep 8;5:78. doi: 10.1186/1742-4690-5-78.


Highly divergent subtypes and new recombinant forms prevail in the HIV/AIDS epidemic in Angola: new insights into the origins of the AIDS pandemic.

Bártolo I, Rocha C, Bartolomeu J, Gama A, Marcelino R, Fonseca M, Mendes A, Epalanga M, Silva PC, Taveira N.

Infect Genet Evol. 2009 Jul;9(4):672-82. doi: 10.1016/j.meegid.2008.05.003. Epub 2008 May 9.


Supplemental Content

Loading ...
Support Center